openPR Logo
Press release

Nanoscale Virus Trap Molecule Market

06-19-2017 04:46 PM CET | Health & Medicine

Press release from: Pharmaceutical Report By CMI

Advancement into scientific research has led to the emergence of new technologies that has the potential to improve drug delivery and effectiveness. With evolution, things are becoming miniature in size, be it electronic chips, medical devices, or pharmaceutical drug. However, miniaturization, also referred as nanotechnology, doesn’t compromise on the product quality and effectiveness. Instead there is improved quality and features delivered via this technology.
Nanotechnology has a real potential to revolutionize the medical treatment procedures, and tools making it more personalized, effective, safe and cheaper. Nanotechnology involves research of molecules that only 1/100th size of cancer cells but has the potential to improve the quality of life. Significant progress has already been made in nanomaterial in terms of developing targeted drug therapies. Some of the developments in nanotechnology include Quantum dots that can enhance biological imaging for medical diagnostics, antibody-nanoparticle complex for early diagnosis of atherosclerosis, use of nanoscale components in molecular imaging, and regeneration or spurring the growth of nerve cells.
The Virus ‘trap’ Nanoparticle
One of the recent progresses made in nanotechnology is the technique of combating viruses before they can infect the host cells. Researchers at Charles Stark Draper Laboratory, the Massachusetts Institute of Technology, the Univ. of Massachusetts Medical School, and the Univ. of Santa Barbara have developed nanoparticles that act as viral ‘traps’ inside the human body. These molecules are surfaced with numerous carbohydrate molecules that closely resemble those targeted by flu viruses. The flu viruses bind to these nanotraps instead of host cell and are eliminated from the body through mucus.
The nanoscale viral trap molecule technology can also be applicable in diagnosing a viral disease. An innovative tunable device selectively traps viruses detecting them with 100 times better sensitivity than the current available techniques. Researchers at the Pennsylvania State University developed this tool that can trap virus and remove majority of the host contaminants.

Request a sample copy of this report@
https://www.coherentmarketinsights.com/insight/request-sample/44

The Technology is Under Research
The nanoparticle molecule is composed of compounds found naturally in the human body. Hence, it is safe as an inhalant, intravenous treatment, or topical solution, and inexpensive to manufacture. Extensive benefits of this technology imply a very high commercial potential in the treatment of viral infections.  Moreover, this technology has shown to be effective in mice. Further research in this may lead to use it against HIV virus, Herpes Simplex Virus (HSV), and Respiratory Syncytial Virus (RSV), as well as bacteria and toxins. With increasing resistance to anti-viral drugs, need for novel therapies are realized. This will further help boost the demand for nanoscale virus trap molecules in the treatment of viral diseases.

However, there are more alternate therapies under research which can compete with the viral trap molecule business. Double-stranded RNA Activated Caspase Oligomerizer (DRACO) is a nanoparticle based drug under research which is designed to detect virally infected cells and eradicate only those cells from the body. Few in-vivo and in-vitro trials have proven this drug to be very effective against different viral strains. The researchers at Charles Stark Draper Laboratory believe that this drug will be ready for clinical trials in next three to eight years.
Conclusion
The viral trap molecule is poised to make contributions far beyond the therapies and tools that have been explored so far. Adequate funding to this research will continue to drive the efforts in commercializing this technology.

Get More Details about this Report@
https://www.coherentmarketinsights.com/ongoing-insight/nanoscale-virus-trap-molecule-market-44

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com
Visit Coherent Market Insights Blog @ https://blog.coherentmarketinsights.com
Connect with us on LinkedIn @ https://www.linkedin.com/company/coherent-market-insights

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Nanoscale Virus Trap Molecule Market here

News-ID: 585530 • Views: 264

More Releases from Pharmaceutical Report By CMI

Rising prevalence of diabetes is a major factor driving growth of the diabetic f …
Diabetic foot ulcers is a common condition in diabetic patients. It is a disabling disorder, which might lead to amputation of the leg. Mortality due to diabetic foot ulcers is high and chances of recurrence of cured foot ulcers is also high and this in turn leads to increasing demand for proper treatment of diabetic foot ulcers. Diabetic foot ulcer is caused due to neuropathic and vascular changes in the
Glucagon-Like Peptide-1 (Glp-1) Analogs Market Global Industry Insights, Trends, …
Glucagon-like peptide-1 (GLP-1) analogs also known as incretin mimetics are class of drugs indicated for type-2 diabetes mellitus to lower the blood sugar level. GLP-1 analogs prevents the breakdown of GLP-1, thereby enhancing the glucose depended insulin release, suppresses the glucagon release (which reduces hepatic glucose output), and reduces gastric emptying rate (resulting in weight loss from reduced appetite). GLP-1 analogs do not cause hypoglycemia like other class of anti-diabetic
Multiple Sclerosis Therapeutics Market to Surpass US$ 24.4 Billion by 2025
Increasing prevalence of multiple sclerosis to augment market growth Multiple sclerosis is a widespread disabling neurological condition, mostly diagnosed in people in the age group 20–50 years. According to the Multiple Sclerosis Foundation, 2017, this autoimmune condition affects 2.5 million people with the global incidence of around 7 cases per 100,000 people per year. The study also states that prevalence rates varies between ethnic and geographical latitudes, ranging from 50 to
Diabetic Foot Ulcers Treatment Market to Surpass US$ 9.49 Billion Threshold by 2 …
Diabetic foot ulcers is a common condition in diabetic patients. It is a disabling disorder, which might lead to amputation of the leg. Mortality due to diabetic foot ulcers is high and chances of recurrence of cured foot ulcers is also high and this in turn leads to increasing demand for proper treatment of diabetic foot ulcers. Diabetic foot ulcer is caused due to neuropathic and vascular changes in the

All 5 Releases


More Releases for Coherent

Coherent Optical Equipment Market Size, Share, Development by 2024
Global Info Research offers a latest published report on Coherent Optical Equipment Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. The report contains 102 pages which highly exhibit on current market analysis scenario, upcoming as well as future opportunities, revenue growth, pricing and profitability. Click to view the full report TOC, figure and tables: https://www.globalinforesearch.com/global-coherent-optical-equipment-market_p107267.html   Coherent optical equipment refers to all the
PHASE-XS – A New Proprietary Database of Coherent Market Insights
PHASE-XS is a database developed by Coherent Market Insights, a market intelligence and consulting company. This database provides clinical information about phase 3 and phase 4 products for biologics and biosimilars. Information related to trial design, current phase, patent expiry, indication, technology, therapeutic category, approved indications, end point analysis, research locations, dosage, physician-administered or self-administered, route of administration, update, reimbursement, addressable patient population, and more of key data is included
PHASE-XS – A New Proprietary Database of Coherent Market Insights
PHASE-XS is a database developed by Coherent Market Insights, a market intelligence and consulting company. This database provides clinical information about phase 3 and phase 4 products for biologics and biosimilars. Information related to trial design, current phase, patent expiry, indication, technology, therapeutic category, approved indications, end point analysis, research locations, dosage, physician-administered or self-administered, route of administration, update, reimbursement, addressable patient population, and more of key data is included
Semiconductor Lasers Market: ASML, Axcel Photonics, Coherent, IPG Photonics, New …
MarketResearchReports.Biz announced the analysis report titled "Global Semiconductor Lasers Market": Industry Analysis, Size, Share, Growth, Trends, and Forecasts. The Semiconductor Lasers Market has been comprehensively detailed in the report with special focus on a range of key elements such as market share, forecast and base figures, CAGR, driving factors, growth restraints, and business opportunities. Buyers of the report are expected to be informed about significant improvements in the market and its
New Report By Coherent Market Insights: Zika Vaccines Market
Zika vaccines are developed for immunization & prevention against diseases caused by Zika virus. This virus belongs to genus Flavivirus and is transmitted by Aedes mosquitoes. The virus can also be transmitted through blood transfusion, sexual contact or from infected pregnant women to the fetus. Diagnosis of this infection is confirmed by detecting viral DNA through PCR. However, only 1 in 4 people with zika infection are prone to develop
Coherent Market Insights
Third party logistics (TPL or 3PL), is a service provider outsourced by a company in a supply chain management or logistic. Increasing globalization for trade offers manufacturing companies with a worldwide networking platform. Companies majorly focus on keeping up with their productivity, and thus rely on third party logistics to suffice their transportation and packaging. This in turn, has driven growth of the market for third part logistics. Growing e-commerce